Mebendazole Inexplicably Reducing the Breast Cancer Cells Viability Preclinically by Incitement Effects with Methotrexate
Objective: To perform preclinical (in vitro) interventional trial of mebendazole.
Methods: This study carried out in Basic Medical Science Institute, JMPC in alliance with PCMD. The total study duration from March 2016 to February 2017. For assessment of cytotoxic incitement effects of mebendazole with methotrexate we used six different dilutions of mebendazole (1.5µM - 100µM) both as alone and in combination with methotrexate (0.5µM-100µM). Cytotoxicity was assessed by MTT and trypan blue dye exclusion cytotoxicity assays. We used primarily two breast cancerous cell lines MCF-7 (representative of invasive ductal carcinoma) and MDA-MB-231 (representative of adenocarcinoma).
Results: Mebendazole more effectively reducing the % viability of studied cancerous cell lines as combination therapy with methotrexate. The average percentage decrease of % viability of MCF-7 and MDA-MB-231 were -81.3097 and -66.8711 respectively. This combination showed selectivity towards cancerous cell lines as indicated by non-significant (p=0.183) effects on normal breast epithelial cell line (MCF-10).
Conclusion: This study demonstrated that combination therapy of mebendazole with standard chemotherapeutic agent methotrexate unveil incitement effects.
Copyright (c) 2018 RADS Journal of Pharmacy and Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.